sábado, 14 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 23, 2026

AS-i Harju Elekter Group majandustulemused, 1-3/2026

View original at globenewswire.com
“Perioodi puhaskasum 192 636-99,3%”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lithuania unit's persistently low sales and resulting high idle production capacity indicate market challenges and the need for more effective sales organisation

    60% confidence
  • Selling expenses grew 45.2% to 1.9 million EUR, driven by growth in marketing and sales services to support market activity, including participation in international trade fairs to strengthen visibility and showcase HECON EVO and Elektra Sense developments

    60% confidence
  • Middle East geopolitical tensions affect Harju Elekter primarily indirectly through global supply chains, logistics, and input prices; instability in international transport channels extends delivery times and raises freight costs

    60% confidence
  • The majority of Estonian, Swedish, and Finnish unit results will materialize in Q2 and Q3, when substation deliveries to framework contract customers begin

    60% confidence
  • Q1 2026 was considerably more difficult than expected and results did not meet expectations; the primary cause was supply chain disruptions that delayed deliveries and pushed order fulfillment to subsequent periods

    60% confidence
  • Uneven material flow disrupts planned work organisation, causes temporary stoppages, and loads production floor space, making resource management and production planning more complex than usual

    60% confidence
  • Both Estonian and Swedish unit order books are above average; a significant portion of pending orders is expected to materialize as revenue in the current financial year

    60% confidence
  • The company approaches the full year 2026 with moderate optimism but caution, as there are signs of a possible new crisis

    60% confidence
  • Material and component price increases will add to already long delivery times in the near future; first signals and new price lists have been received from suppliers; positive P&L impact expected with 1–2 quarter lag via framework contract indexation

    60% confidence
  • Rapid cost reduction is not possible without risking the inability to respond quickly enough to growing demand; retaining competency, team readiness, and capacity to respond when peak season arrives are strategically critical

    60% confidence
  • No order cancellations have occurred to date, but customer behaviour shows caution

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
AS-i Harju Elekter Group majandustulemused, 1-3/2026 — Source | Via News | pt.VIA.NEWS